



Abbott Pakistan

Un-Audited Financial Statements for the
Quarter and Nine Months Ended September 30, 2014



Abbott
A Promise for Life

Corporate Information

Board Of Directors

Munir A. Shaikh (Chairman)
Arshad Saeed Husain
(Chief Executive Officer)
Kamran Y. Mirza
Ehsan Ali Malik
Syed Anis Ahmed
Atif Aslam Bajwa
Shamim Ahmad Khan

Audit Committee

Ehsan Ali Malik (Chairman)
Shamim Ahmad Khan
Kamran Y. Mirza
Maria Memon
(Chief Internal Auditor - by Invitation)
Syed Anis Ahmed (CFO - by Invitation)

Human Resource and Remuneration Committee

Munir A. Shaikh (Chairman)
Atif Aslam Bajwa
Arshad Saeed Husain
Shamim Ahmad Khan
Shahrukh Masood (Secretary)

Share Transfer Committee

Arshad Saeed Husain (Chairman)
Syed Anis Ahmed
Kamran Y. Mirza

Banking Committee

Atif Aslam Bajwa (Chairman)
Arshad Saeed Husain
Syed Anis Ahmed

Chief Financial Officer

Syed Anis Ahmed

Company Secretary

Malik Saadatullah

Auditors

Ernst & Young Ford Rhodes
Sidat Hyder & Company,
(a member firm of Ernst & Young)
Chartered Accountants

Legal Advisors

Orr, Dignam & Co.
SurrIDGE & Beecheno

Share Registrar

FAMCO Associates (Pvt) Ltd.
8-F, Next to Hotel Faran, Nursery, Block 6,
P.E.C.H.S, Shahrah-e-Faisal, Karachi.

Bankers

Faysal Bank Limited
Citibank N.A.
Deutsche Bank AG
MCB Bank Limited
National Bank of Pakistan
Standard Chartered Bank
(Pakistan) Limited
The Bank of Tokyo-Mitsubishi UFJ Limited
Barclays Bank PLC

Registered Office

Opposite Radio Pakistan
Transmission Centre,
Hyderabad Road, Landhi,
P.O. Box 7229, Karachi Pakistan.

City Office

8th Floor, Faysal House,
St-02, Shahrah-e-Faisal, Karachi Pakistan.

Website

www.abbott.com.pk

Senior Management Team

Arshad Saeed Husain
(Chief Executive Officer)
Syed Anis Ahmed (Chief Financial Officer)
Anis A. Shah (Director Plant Operations)
Asim Shafiq (General Manager, Abbott
Nutrition International Pakistan)
Habib Ahmed
(Country Manager, Abbott Diagnostics
Division Pakistan)
Dr. Sheikh Adnan Lateef
(Head of Abbott Diabetes Care Pakistan)
Dr. Farrukh Hafeez
(Director Quality Assurance)
Dr. Sarmad Maqbool
(Director Marketing & Strategy)
Seema Khan (Director Regulatory Affairs)
Dr. Raeeef Ahmed (Director Medical Affairs)
Shahrukh Masood
(Director Human Resources)
Dr. Suleman Alvi
(Director Business Development)
Rana A. Latif
(Director Manufacturing)
Zahid Hussain
(Director Materials Management)

Directors' Report

The Directors are pleased to present their Report and accounts of the Company for the third quarter ended September 30th, 2014.


FINANCIAL RESULTS

Sales for the quarter increased by 13% over the same period last year. Pharmaceutical sales increased by 13%, Nutritionals by 16% and Others by 8%. Gross profit to sales ratio was at 37% compared to last year of 39%, mainly due to devaluation of Pak rupee.

FUTURE OUTLOOK

Despite increasing cost of doing business, there is still absence of systematic price increase mechanism. We look forward to the Government for adoption of a pragmatic approach, facilitating the industry to address its long outstanding issues including pricing which would facilitate sustained supply of quality medicines to the public.

KARACHI: October 23rd, 2014



Munir A. Shaikh
Chairman

Condensed Interim Balance Sheet

As at September 30, 2014

	UNAUDITED SEPTEMBER 30, 2014	AUDITED DECEMBER 31, 2013
Note	----- (Rupees '000) -----	
Non-Current Assets		
Fixed Assets		
- Property, plant and equipment	3,307,816	3,183,735
- Intangible asset	28,700	41,615
	<u>3,336,516</u>	<u>3,225,350</u>
Long-term loans and advances	44,119	31,896
Long-term deposits	7,664	4,103
Long-term prepayments	9,970	8,065
	<u>61,753</u>	<u>44,064</u>
Total Non-Current Assets	3,398,269	3,269,414
Current Assets		
Stores and spares	95,226	107,238
Stock-in-trade	3,332,382	2,762,690
Trade debts	500,051	546,093
Loans and advances - considered good	133,981	172,205
Trade deposits and short-term prepayments	187,811	154,613
Accrued profit	13,941	5,922
Other receivables	157,468	79,269
Taxation recoverable	2,512	173,509
Cash and bank balances	<u>5,218,731</u>	<u>3,897,051</u>
	<u>9,642,103</u>	<u>7,898,590</u>
Current Liabilities		
Trade and other payables	<u>2,733,113</u>	<u>2,217,177</u>
	<u>2,733,113</u>	<u>2,217,177</u>
Net Current Assets	6,908,990	5,681,413
Total Assets Less Current Liabilities	10,307,259	8,950,827
Non-Current Liability		
Deferred taxation	205,743	203,562
Contingencies and Commitments		
NET ASSETS	10,101,516	8,747,265
FINANCED BY:		
Share Capital and Reserves		
Authorised capital		
200,000,000 ordinary shares of Rs.10 each	<u>2,000,000</u>	<u>2,000,000</u>
Issued, subscribed and paid-up capital	979,003	979,003
Reserves - capital	330,701	300,030
- revenue	<u>8,791,812</u>	<u>7,468,232</u>
SHAREHOLDERS' EQUITY	10,101,516	8,747,265

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE



SYED ANIS AHMED
DIRECTOR

Condensed Interim Profit and Loss Account (Unaudited)

For The Quarter And Nine Months Ended September 30, 2014

	Jul - Sep 2014	Jan - Sep 2014	Jul - Sep 2013	Jan - Sep 2013
	----- (Rupees '000) -----			
Sales - net				
Domestic	4,437,135	13,408,185	3,929,998	11,851,254
Export	271,566	633,603	235,290	529,351
	4,708,701	14,041,788	4,165,288	12,380,605
Service fee for toll manufacturing	-	-	1,314	8,214
	4,708,701	14,041,788	4,166,602	12,388,819
Cost of goods sold and services	2,949,550	8,752,842	2,527,465	7,580,604
Gross profit	1,759,151	5,288,946	1,639,137	4,808,215
Selling and distribution expenses	638,368	2,025,752	623,015	1,846,855
Administrative expenses	91,607	294,033	90,184	265,288
	1,029,176	2,969,161	925,938	2,696,072
Other income	95,071	343,407	66,578	190,098
Other charges	88,157	259,245	98,938	282,429
	1,036,090	3,053,323	893,578	2,603,741
Finance cost	1,149	3,137	667	2,058
Profit before taxation	1,034,941	3,050,186	892,911	2,601,683
Taxation				
- current	374,354	1,039,123	289,944	869,024
- deferred	(20,559)	2,181	(11,931)	(21,331)
	353,795	1,041,304	278,013	847,693
Profit for the period	681,146	2,008,882	614,898	1,753,990
	----- (Rupees) -----			
Earnings per share - basic / diluted	6.96	20.52	6.28	17.92

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

Condensed Interim Statement of Comprehensive Income (Unaudited)

For The Quarter And Nine Months Ended September 30, 2014

	Jul - Sep 2014	Jan - Sep 2014	Jul - Sep 2013	Jan - Sep 2013
	----- Rupees in ' 000 -----			
Profit for the period	681,146	2,008,882	614,898	1,753,990
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	<u>681,146</u>	<u>2,008,882</u>	<u>614,898</u>	<u>1,753,990</u>

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE



SYED ANIS AHMED
DIRECTOR

Condensed Interim Cash Flow Statement (Unaudited)

For The Nine Months Ended September 30, 2014

		Jan - Sep 2014	Jan - Sep 2013
Note		----- (Rupees '000) -----	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	6	2,970,524	2,548,125
Income taxes paid		(868,126)	(683,080)
Long-term loans and advances - net		(12,223)	6,437
Long-term deposits - net		(3,561)	(425)
Long-term prepayments - net		(1,905)	864
Net cash inflow from operating activities		2,084,709	1,871,921
CASH FLOWS FROM INVESTING ACTIVITIES			
Fixed capital expenditure		(465,150)	(713,894)
Sale proceeds from disposal of fixed assets		37,638	22,863
Interest income		305,358	169,632
Net cash outflow from investing activities		(122,154)	(521,399)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance cost paid		(3,137)	(2,058)
Dividend paid		(637,738)	(678,585)
Net cash outflow from financing activities		(640,875)	(680,643)
Net increase in cash and cash equivalents		1,321,680	669,879
Cash and cash equivalents at the beginning of the period		3,897,051	2,790,212
Cash and cash equivalents at the end of the period		5,218,731	3,460,091

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

Condensed Interim Statement of Changes in Equity (Unaudited)

For The Nine Months Ended September 30, 2014

Share Capital	Reserves					Total Equity
	Capital Reserves		Revenue Reserves		Total	
	Reserve Arising on Merger	Other	General Reserve	Un-appropriated Profit		
Rupees '000						

(Rupees '000)

Balance as at December 31, 2012 979,003 46,097 216,211 3,588,422 1,877,661 5,728,391 6,707,394

Transfer from unappropriated profit to general
reserve made subsequent to the period
ended December 31, 2012

- - - 1,750,000 (1,750,000) - -

Total comprehensive income for the nine months
ended September 30, 2013

Profit for the period

-	-	-	-	1,753,990	1,753,990	1,753,990
-	-	-	-	-	-	-

Other comprehensive income for
the period, net of tax

Total comprehensive income for the period

- - - - 1,753,990 1,753,990 1,753,990

Transactions with owners, recorded directly in equity

Final dividend for the year ended December 31,
2012 declared subsequent to the
year end @ Rs. 4 per share

- - - - (391,601) (391,601) (391,601)

Interim dividend for the year ending
December 31, 2013 @ Rs. 3 per share

- - - - (293,701) (293,701) (293,701)

Capital contribution from Abbott International LLC,
USA in relation to share based compensation

- - 26,533 - - 26,533 26,533

Balance as at September 30, 2013

979,003 46,097 242,744 5,338,422 1,196,349 6,823,612 7,802,615

Balance as at December 31, 2013

979,003 46,097 253,933 5,338,422 2,129,810 7,768,262 8,747,265

Total comprehensive income for the nine months
ended September 30, 2014

Profit for the period

-	-	-	-	2,008,882	2,008,882	2,008,882
-	-	-	-	-	-	-

Other comprehensive income for
the period, net of tax

Total comprehensive income for the period

- - - - 2,008,882 2,008,882 2,008,882

Transactions with owners, recorded directly in equity

Final dividend for the year ended December 31,
2013 declared subsequent to the
year end @ Rs. 4 per share

- - - - (391,601) (391,601) (391,601)

Interim dividend for the year ending
December 31, 2014 @ Rs. 3 per share

- - - - (293,701) (293,701) (293,701)


Capital contribution from Abbott International LLC,
USA in relation to share based compensation

- - 30,671 - - 30,671 30,671

Balance as at September 30, 2014

979,003 46,097 284,604 5,338,422 3,453,390 9,122,513 10,101,516

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

1. THE COMPANY AND ITS OPERATIONS

"Abbott Laboratories (Pakistan) Limited (The Company) is a public limited company incorporated in Pakistan on July 2, 1948, and its shares are quoted on the Karachi, Lahore and Islamabad stock exchanges. The address of its registered office is opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of research based pharmaceutical, nutritional, diagnostic, diabetic care, molecular devices, hospital and consumer products and in providing toll manufacturing services.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

Statement of compliance

This condensed interim financial information has been prepared in accordance with the requirements of the International Accounting Standard 34 – "Interim Financial Reporting" and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed. This condensed interim financial information does not include all of the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Company as at and for the year ended December 31, 2013.

This condensed interim financial information is being submitted to the shareholders as required by the Listing Regulations of Karachi, Lahore and Islamabad stock exchanges and section 245 of the Companies Ordinance, 1984.

2.2 Accounting policies

The accounting policies and the methods of computation used in the preparation of this condensed interim financial information are the same as those applied in the preparation of the financial statements for the preceding year ended December 31, 2013.

2.3 Accounting estimates and judgments.

The preparation of condensed interim financial information in conformity with approved accounting standards, as applicable in Pakistan requires the management to make estimates, assumptions and use judgments that affect the application of policies and the reported amount of assets and liabilities and income and expenses.

Estimates and judgments made by management in the preparation of this condensed interim financial information are the same as those that were applied to the audited annual financial statements of the Company as at and for the year ended December 31, 2013.

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

	UNAUDITED Jan - Sep 2014	UNAUDITED Jan - Sep 2013
	----- (Rupees '000) -----	
3. PROPERTY, PLANT AND EQUIPMENT [COST OF ADDITIONS / (DELETIONS)]		
Plant and machinery	100,964 (25,250)	99,858 (14,135)
Buildings on freehold land	1,782	13,901
Office equipment	2,533 (2,470)	- -
Vehicles	66,562 (54,076)	48,038 (42,358)
Computers	16,987 (1,523)	62,704 (812)
Demonstration equipments	138,079 (110,874)	305,377 (19,767)
Capital work in progress (CWIP) - net	138,243	188,562
Additions net off CWIP	<u>465,150</u>	<u>718,440</u>
Total (deletions)	<u>(194,193)</u>	<u>(77,072)</u>

4. CONTINGENCIES AND COMMITMENTS

4.1 Contingencies

4.1.1 The Company has given bank guarantees of Rs. 128.862 million (December 31, 2013: Rs 111.980 million) to the Customs Department, a utility company and other institutions against tenders.

4.1.2 The returns of total income for four tax years (Tax Years 2005 – 2008) were selected for audit by the tax authority. The Taxation Officer disallowed certain expenses claimed by the Company against which the Company filed appeals before the Commissioner Inland Revenue (Appeals) [CIR(A)]. The CIR(A) allowed certain expenses, however, maintained majority of the disallowances resulting in tax demand of Rs. 239.695 million. The Company has now filed the appeals before the Appellate Tribunal Inland Revenue (ATIR) which are pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. However, being prudent, management has made a provision of Rs. 156 million (December 31, 2013: 30 million) in the financial statements.

4.1.3 The Company has filed a reference application before the High Court of Sindh for assessment years 1997-98, 1999-00 to 2002-03 in respect of certain disallowances resulting in a tax demand of Rs 154.500 million, which is pending adjudication.

Management is of the view that the position of the Company is sound and eventual outcome is expected to be in Company's favour. However, being prudent, management has made a provision of entire tax demand in the financial statements.

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

4.2 Commitments

4.2.1 Commitments for capital expenditure as at September 30, 2014 aggregated to Rs. 79,805 million (December 31, 2013: Rs. 90,475 million).

4.2.2 The Company has obtained short term financing facilities from various commercial banks amounting to Rs.1,080 million (December 31, 2013: Rs. 1,397 million). These facilities can be utilized for letters of credit, guarantees and running finance / short term loans. However, the running finance / short term loan utilization cannot exceed Rs. 310 million (December 31, 2013: Rs. 310 million). The running finance / short term loan carries markup at rates ranging from KIBOR plus 1% to KIBOR plus 2% (December 31, 2013: KIBOR plus 1% to KIBOR plus 2%) and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not borrowed any amount against running finance / short term loan facilities at the balance sheet date. Commitments in respect of letters of credit as at balance sheet date aggregated to Rs. 367.885 million (December 31, 2013: Rs. 396.908 million).

5. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at September 30, 2014, Abbott Asia Investments Limited, UK held 76,259,454 (December 31, 2013: 76,259,454) shares. The ultimate holding company is Abbott International LLC, USA.

	UNAUDITED Jan - Sep 2014	UNAUDITED Jan - Sep 2013
Note	----- (Rupees '000) -----	
6. CASH GENERATED FROM OPERATIONS		
Profit before taxation	3,050,186	2,601,683
Adjustment for:		
Depreciation	312,841	293,529
Amortisation on intangible asset	12,915	12,915
Gain on disposal of fixed assets	(9,410)	(2,495)
Income on investments and deposits	(313,376)	(170,780)
Expense recognised in profit or loss in respect of equity-settled share-based payments	30,671	26,533
Finance cost	3,137	2,058
Working capital changes	(116,439)	(215,318)
6.1	<u>2,970,524</u>	<u>2,548,125</u>

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

	UNAUDITED Jan - Sep 2014	UNAUDITED Jan - Sep 2013
	----- (Rupees '000) -----	
6.1 Working capital changes		
(Increase) / decrease in current assets net of provision		
Stores and spares	12,012	6,365
Stock-in-trade	(569,692)	(518,216)
Trade debts	46,042	94,643
Loans and advances	38,224	(163,688)
Trade deposits and short-term prepayments	(33,198)	(62,614)
Other receivables	(78,199)	(15,730)
	<u>(584,811)</u>	<u>(659,240)</u>
Increase in current liabilities		
Trade and other payables - net	468,372	443,922
	<u>(116,439)</u>	<u>(215,318)</u>

7. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise other related parties, employee retirement benefit plans, directors and key management personnel. Transactions with related parties essentially entail sale and purchase of goods and services and expenses charged between these parties. Transactions with related parties are as follows:

	UNAUDITED Jan - Sep 2014	UNAUDITED Jan - Sep 2013
	----- (Rupees '000) -----	
Other related parties		
Sale of goods	77,615	69,398
Purchase of materials	2,924,881	1,417,972
Technical service fee	97,513	87,730
Reimbursements from a related party on account of:		
Selling and distribution expenses	60,435	48,728
Administrative expenses	9,134	5,347
Interest income earned	11,987	16,434
Charge in respect of staff retirement benefit plans:		
Pension fund	104,720	90,824
Provident fund	51,458	44,529
Key management personnel		
Short-term employee benefits	130,176	116,544
Post-employment benefits	16,513	13,807

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

8. SEGMENT ANALYSIS

8.1 Segment wise operating results for the third quarter:

	UNAUDITED				UNAUDITED			
	Jul - Sep				Jul - Sep			
	2014				2013			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
(Rupees '000)								
Sales	3,561,508	861,983	431,334	4,854,825	3,128,979	743,865	421,945	4,294,790
Less:								
Sales return and discount	38,202	1,261	4,157	43,620	12,872	-	5,806	18,678
Sales tax and excise duty	-	84,744	17,760	102,504	-	74,077	36,746	110,823
Sales - net	3,523,306	775,978	409,417	4,708,701	3,116,107	669,788	379,393	4,165,288
Service fee for toll manufacturing	-	-	-	-	1,314	-	-	1,314
	3,523,306	775,978	409,417	4,708,701	3,117,421	669,788	379,393	4,166,602
Cost of goods sold and services	2,194,942	462,958	291,650	2,949,550	1,854,727	409,198	263,540	2,527,465
Gross profit	1,328,364	313,020	117,767	1,759,151	1,262,694	260,590	115,853	1,639,137
Selling and distribution expenses	487,259	87,223	63,886	638,368	436,587	78,859	107,569	623,015
Administrative expenses	82,422	4,842	4,343	91,607	74,447	11,392	4,345	90,184
Segment result	758,683	220,955	49,538	1,029,176	751,660	170,339	3,939	925,938

8.2 Segment wise operating results for nine months:

	UNAUDITED				UNAUDITED			
	Jan - Sep				Jan - Sep			
	2014				2013			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
(Rupees '000)								
Sales	10,729,794	2,364,961	1,335,440	14,430,195	9,277,586	2,063,189	1,391,530	12,732,305
Less:								
Sales return and discount	76,360	2,149	7,672	86,181	29,842	3,320	7,692	40,854
Sales tax and excise duty	-	224,711	77,515	302,226	-	193,702	117,144	310,846
Sales - net	10,653,434	2,138,101	1,250,253	14,041,788	9,247,744	1,866,167	1,266,694	12,380,605
Service fee for toll manufacturing	-	-	-	-	1,314	-	6,900	8,214
	10,653,434	2,138,101	1,250,253	14,041,788	9,249,058	1,866,167	1,273,594	12,388,819
Cost of goods sold and services	6,521,306	1,356,585	874,951	8,752,842	5,599,108	1,167,278	824,218	7,580,604
Gross profit	4,132,128	781,516	375,302	5,288,946	3,649,950	708,889	449,376	4,808,215
Selling and distribution expenses	1,484,638	308,297	232,817	2,025,752	1,329,482	266,411	250,962	1,846,855
Administrative expenses	259,103	22,380	12,550	294,033	217,599	36,780	10,909	265,288
Segment result	2,388,387	450,839	129,935	2,969,161	2,102,869	405,698	187,505	2,696,072

Selected Notes to the Condensed Interim Financial Information (Unaudited)

For The Nine Months Ended September 30, 2014

8.3 Reconciliation of segment results with profit before taxation

	UNAUDITED Jul - Sep 2014	UNAUDITED Jan - Sep 2014	UNAUDITED Jul - Sep 2013	UNAUDITED Jan - Sep 2013
	----- (Rupees '000) -----			
Total segment results	1,029,176	2,969,161	925,938	2,696,072
Other income	95,071	343,407	66,578	190,098
Other charges	88,157	259,245	98,938	282,429
Finance cost	1,149	3,137	667	2,058
Profit before taxation	1,034,941	3,050,186	892,911	2,601,683
			UNAUDITED Jan - Sep 2014	UNAUDITED Jan - Sep 2013

8.4 Geographical information

Sales to external customers


Pakistan	13,408,185	11,859,468
Afghanistan	522,260	408,576
Srilanka	30,227	42,777
Netherland	11,426	66,680
Bangladesh	3,501	8,600
Switzerland	66,189	2,718
	<u>14,041,788</u>	<u>12,388,819</u>

8.5 Segment Assets

	UNAUDITED September 30, 2014				AUDITED December 31, 2013			
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
	----- (Rupees '000) -----							
Segment assets employed	5,770,424	552,626	1,136,551	7,459,601	5,255,722	428,253	1,046,695	6,730,670
Unallocated corporate assets				5,580,771				4,437,334
Total reported assets				<u>13,040,372</u>				<u>11,168,004</u>

9. DATE OF AUTHORISATION

This condensed interim financial information was authorised for issue on October 23, 2014 by the Board of Directors of the Company.


ARSHAD SAEED HUSAIN
CHIEF EXECUTIVE


SYED ANIS AHMED
DIRECTOR

ABBOTT LABORATORIES (PAKISTAN) LIMITED

Registered Office

Opposite Radio Pakistan
Transmission Centre, Hyderabad Road,
Landhi, P.O. Box 7229, Karachi
Phone :111-ABBOTT, (111-222-688)
Fax: (92-21) 35001903

City Office

8th Floor, Faysal House,
St-02, Shahrah-e-Faisal, Karachi
Phone: (92-21) 32799018, 32799019
Fax: (92-21) 32800244
URL: www.abbott.com.pk

